Author
Beth Israel Deaconess Medical CenterORCID 0000-0001-5481-0090Unclaimed ORCID profile · follow to get notified of new preprints
3 papers
Recent·Most cited
Fen Ma, Sen Chen, Luigi Giovanni Cecchi…·Steven P. Balk
This study shows that in prostate cancer with TMPRSS2:ERG fusion, androgen deprivation increases AKT activation, which may reduce the effectiveness of AR-targeted therapy, suggesting combination therapy could be beneficial.
Larysa Poluben, Mannan Nouri, Jiaqian Liang…·Steven P. Balk
This study shows that ARv7 drives AR activity in castration-resistant prostate cancer through increased chromatin accessibility mediated by NFI factors.
Meng Xiao He, Michael S. Cuoco, Jett P. Crowdis…·Eliezer M. Van Allen
This study identifies transcriptional states in mCRPC that mediate treatment resistance, including AR splicing heterogeneity, TGF-β signaling, and immune infiltration patterns.